Amgen Inc. which can be found using ticker (AMGN) have now 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $381.00 and $200.00 suggesting an average Analsyt target price of $329.14. Now with the previous closing price of $312.86 this indicates there is a potential upside of 5.2%. Also worth taking note is the 50 day moving average now sits at $328.88 while the 200 day moving average is $302.83. The company has a market capitalization of 171.46B. The price for the stock stands currently at: $319.10 USD
The potential market cap would be $180,383,879,149 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 54.92, revenue per share of $57.66 and a 4.48% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
